Adherence and Persistence to Biological Drugs for Psoriasis: Systematic Review with Meta-Analysis

Piragine, Eugenia; Petri, Davide; Martelli, Alma; Janowska, Agata; Dini, Valentina; Romanelli, Marco; Calderone, Vincenzo; Lucenteforte, Ersilia

doi:10.3390/jcm11061506

Cited by 22 publications

(12 citation statements)

References 113 publications

(317 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our results seem to be in line with what has already been observed in the literature. Several studies observed higher adherence in patients treated with ustekinumab and lower adherence in those treated with etanercept [ 13 , 14 , 15 , 16 ]. Moreover, it was observed that patients treated with etanercept had a higher percentage of switches to other biologics, whereas patients treated with ustekinumab had the lowest percentage of switches [ 13 ].…”

Section: Discussionmentioning

confidence: 99%

Use of Biological Drugs for Psoriasis: A Drug-Utilization Study Using Tuscan Administrative Databanks

Giometto

Tillati

Baglietto

et al. 2022

IJERPH

Self Cite

View full text Add to dashboard Cite

Our study aims at providing evidence on patterns of use of biologic drugs for psoriasis in Tuscany, Italy. We conducted a drug-utilization study based on administrative databanks of Tuscany (EUPAS45365) from 2011 to 2019. We selected new users of etanercept, infliximab, adalimumab, ustekinumab, or secukinumab between 1 January 2011 and 31 December 2016. We considered subjects with psoriasis and followed subjects until the end of the study period (three years after the first dispensation of biologic drug for psoriasis) or the patient’s death, whichever came first. We censored subjects for pregnancy or neoplasia. For each subject, we defined the state as the weekly coverage of one of the biologic drugs of interest. We then defined the switch as the change from a state to another one. A total of 7062 subjects with a first dispensation of a PSObio drug in the inclusion period was identified, and 1839 (52.9% female, 51.6 mean age) patients were included in the analysis. Among new users of adalimumab (N = 770, 41.9%), one third showed a continuous behaviour whereas the others moved to etanercept and ustekinumab. New users of etanercept (N = 758, 41.2%), had the highest proportion of switchers, with adalimumab most often being the second choice. New users of infliximab (N = 159, 8.6%) experienced the highest proportion of treatment discontinuation. The present study suggests that the majority of patients treated with PSObio drugs do not switch from one active ingredient to another. However, patients who started biological therapy with etanercept had the highest frequency of switching to other PSObio drugs, whereas those who started with secukinumab or ustekinumab had the lowest.

show abstract

Section: Discussionmentioning

confidence: 99%

Use of Biological Drugs for Psoriasis: A Drug-Utilization Study Using Tuscan Administrative Databanks

Giometto

Tillati

Baglietto

et al. 2022

IJERPH

Self Cite

View full text Add to dashboard Cite

show abstract

“…Of these, the IL-12/IL-23 antibody has shown the best performance in psoriasis treatment; yet the search continues for more effective therapies that offer sustained benefits. [4] One such promising candidate is tildrakizumab, a highaffinity, humanized IgG1 k monoclonal antibody that specifically targets the IL-23 p19 subunit. It demonstrated effective management of moderate-to-severe plaque psoriasis in previous phase III trials (reSURFACE 1 and reSURFACE 2).…”

Section: Introductionmentioning

confidence: 99%

“…Of these, the IL-12/IL-23 antibody has shown the best performance in psoriasis treatment; yet the search continues for more effective therapies that offer sustained benefits. [ 4 ]…”

Section: Introductionmentioning

confidence: 99%

Tildrakizumab for moderate-to-severe plaque psoriasis in Chinese patients: A 12-week randomized placebo-controlled phase III trial with long-term extension

Yu,

Geng,

Yang

et al. 2024

Chinese Medical Journal

View full text Add to dashboard Cite

Background: There is a need for effective and safe therapies for psoriasis that provide sustained benefits. The aim of this study was to assess the efficacy and safety of tildrakizumab, an anti-interleukin-23p19 monoclonal antibody, for treating moderate-to-severe plaque psoriasis in Chinese patients. Methods: In this multi-center, double-blind, phase III trial, patients with moderate-to-severe plaque psoriasis were enrolled and randomly assigned (1:1) to receive subcutaneous tildrakizumab 100 mg or placebo at weeks 0 and 4. Patients initially assigned to placebo were switched to receive tildrakizumab at weeks 12, 16, and every 12 weeks thereafter. Patients in the tildrakizumab group continued with tildrakizumab at week 16, and every 12 weeks until week 52. The primary endpoint was the Psoriasis Area and Severity Index (PASI 75) response rate at week 12. Results: At week 12, tildrakizumab demonstrated significantly higher PASI 75 response rates (66.4% [73/110] vs. 12.7% [14/110]; difference, 51.4% [95% confidence interval (CI), 40.72, 62.13]; P <0.001) and Physician's Global Assessment (60.9% [67/110] vs. 10.0% [11/110]; difference, 49.1% [95% CI, 38.64, 59.62]; P <0.001) compared to placebo. PASI 75 response continued to improve over time in both tildrakizumab and placebo-switching to tildrakizumab groups, reaching maximal efficacy after 28 weeks 86.8% [92/106] vs. 82.4% [89/108] and maintained up to 52 weeks 91.3% [95/104] vs. 87.4% [90/103]. Most treatment-emergent adverse events were mild and not related to tildrakizumab. Conclusion: Tildrakizumab demonstrated durable efficacy through week 52 and was well tolerated in Chinese patients with moderate-to-severe plaque psoriasis. Clinical trial registration: ClinicalTrials.gov, NCT05108766.

show abstract

“…Nonadherence disrupts blood pressure and glucose regulation, reducing the therapeutic efficacy of medications and increasing the chance of side effects. 15 , 16 This exposes patient to increased symptom burden and diminished quality of life. 17 , 18 …”

Section: Introductionmentioning

confidence: 99%

Factors influencing medication adherence in co-morbid hypertension and diabetes patients: A scoping review

Kwakye,

Kretchy,

Peprah

et al. 2024

Exploratory Research in Clinical and Social Pharmacy

View full text Add to dashboard Cite

Adherence and Persistence to Biological Drugs for Psoriasis: Systematic Review with Meta-Analysis

Cited by 22 publications

References 113 publications

Use of Biological Drugs for Psoriasis: A Drug-Utilization Study Using Tuscan Administrative Databanks

Use of Biological Drugs for Psoriasis: A Drug-Utilization Study Using Tuscan Administrative Databanks

Tildrakizumab for moderate-to-severe plaque psoriasis in Chinese patients: A 12-week randomized placebo-controlled phase III trial with long-term extension

Factors influencing medication adherence in co-morbid hypertension and diabetes patients: A scoping review

Contact Info

Product

Resources

About